Wall Street Zen Downgrades OrthoPediatrics (NASDAQ:KIDS) to Sell

OrthoPediatrics (NASDAQ:KIDS) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

A number of other equities research analysts also recently issued reports on KIDS. Weiss Ratings reiterated a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Wednesday, October 8th. Stifel Nicolaus reduced their price target on shares of OrthoPediatrics from $32.00 to $20.00 and set a “buy” rating for the company in a research report on Friday. BTIG Research reduced their price target on shares of OrthoPediatrics from $39.00 to $23.00 and set a “buy” rating for the company in a research report on Friday. Citigroup reiterated an “outperform” rating on shares of OrthoPediatrics in a research report on Friday. Finally, Lake Street Capital reduced their price target on shares of OrthoPediatrics from $37.00 to $34.00 and set a “buy” rating for the company in a research report on Friday. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $26.29.

OrthoPediatrics Price Performance

Shares of NASDAQ:KIDS opened at $16.30 on Friday. The company has a quick ratio of 3.43, a current ratio of 6.66 and a debt-to-equity ratio of 0.27. The company has a market cap of $408.71 million, a P/E ratio of -9.11 and a beta of 1.02. OrthoPediatrics has a 52 week low of $15.28 and a 52 week high of $32.00. The company has a 50-day moving average price of $19.49 and a 200 day moving average price of $20.99.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings data on Monday, January 9th. The company reported ($0.15) EPS for the quarter. The firm had revenue of $25.08 million during the quarter. OrthoPediatrics had a negative net margin of 18.92% and a negative return on equity of 6.36%. Research analysts predict that OrthoPediatrics will post -0.93 earnings per share for the current year.

Insider Activity

In related news, CFO Fred Hite acquired 5,076 shares of the business’s stock in a transaction that occurred on Thursday, August 21st. The stock was purchased at an average cost of $19.41 per share, for a total transaction of $98,525.16. Following the transaction, the chief financial officer directly owned 213,065 shares of the company’s stock, valued at approximately $4,135,591.65. This trade represents a 2.44% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 32.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in OrthoPediatrics by 6.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock worth $246,000 after acquiring an additional 645 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its stake in OrthoPediatrics by 12.4% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,901 shares of the company’s stock worth $342,000 after acquiring an additional 1,753 shares during the period. Invesco Ltd. grew its stake in OrthoPediatrics by 12.1% in the 1st quarter. Invesco Ltd. now owns 18,349 shares of the company’s stock worth $452,000 after acquiring an additional 1,986 shares during the period. American Century Companies Inc. grew its stake in OrthoPediatrics by 12.5% in the 2nd quarter. American Century Companies Inc. now owns 34,486 shares of the company’s stock worth $741,000 after acquiring an additional 3,828 shares during the period. Finally, Birchview Capital LP grew its stake in OrthoPediatrics by 30.0% in the 2nd quarter. Birchview Capital LP now owns 26,000 shares of the company’s stock worth $558,000 after acquiring an additional 6,000 shares during the period. 69.05% of the stock is currently owned by institutional investors and hedge funds.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.